Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23534328 | 0.86 | ESR1 (0.49) | TP53L3MBTL1MAPTHPGDCYP1A2 | |
| SCHEMBL25449 | 0.83 | MAPK1 (0.57) | POLBKMT2ANPSR1L3MBTL1MAPT | |
| SCHEMBL972735 | 0.81 | HPGD (0.43) | POLBKMT2ATHRBTP53MAPT | |
| SCHEMBL14688254 | 0.79 | HPGD (0.46) | POLBMAPTHPGDNPC1RAB9A | |
| SCHEMBL6722955 | 0.79 | HPGD (0.46) | POLBKMT2ATP53NPSR1L3MBTL1 | |
| SCHEMBL4755850 | 0.78 | MAPK1 (0.51) | POLBKMT2AL3MBTL1HPGDNPC1 | |
| SCHEMBL29114933 | 0.77 | RAB9A (0.57) | POLBKMT2ANPSR1L3MBTL1MAPT | |
| SCHEMBL1665229 | 0.77 | DAO (0.58) | POLBKMT2ATHRBTP53NPSR1 | |
| SCHEMBL15981916 | 0.77 | HPGD (0.52) | KMT2AL3MBTL1MAPTHPGDGAA | |
| SCHEMBL1423671 | 0.76 | KMT2A (0.54) | POLBKMT2ATHRBTP53NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676923-A1 | BIARYLAMIDE DERIVATIVES AND THEIR USE AS PKMYT1 INHIBITORS | Cancer Research Technology Limited (GB) | 2026-01-14 | — | — | EP | disclosed |
| WO-2025119300-A1 | MYT1 KINASE INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 广东东阳光药业股份有限公司 | 2025-06-12 | — | — | WO | disclosed |
| CN-120118088-A | Myt1 kinase inhibitor compounds, pharmaceutical compositions thereof and uses thereof | 广东东阳光药业股份有限公司 | 2025-06-10 | — | — | CN | disclosed |
| WO-2024184550-A1 | BIARYLAMIDE DERIVATIVES AND THEIR USE AS PKMYT1 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-09-12 | — | — | WO | disclosed |
| US-20230382924-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-30 | — | — | US | disclosed |
| EP-4225446-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-4217355-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | Forkhead Biotherapeutics, inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230203044-A1 | PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| EP-4135843-A1 | PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | JANSSEN Pharmaceutica NV (BE) | 2023-02-22 | — | — | EP | disclosed |
| CN-115427110-A | Pyrazolo [1,5-D ] [1,2,4] triazine-5 (4H) acetamide as an NLRP3 inflammatory pathway inhibitor | 詹森药业有限公司 | 2022-12-02 | — | — | CN | disclosed |
| EP-1945220-A1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-07-23 | — | — | EP | disclosed |
| CN-101208306-A | Pyrazole compounds and diabetes therapeutic agent containing the same | JAPAN TOBACCO INC (JP) | 2008-06-25 | — | — | CN | disclosed |
| EP-1899304-A1 | 5-AMINO-1H-PYRAZOLE-3-CARBOXYLIC ACID DERIVATIVES AS AGONISTS FOR THE G-PROTEIN COUPLED RECEPTOR (GPCR) RUP38 FOR THE TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | Arena Pharmaceuticals, Inc. (US) | 2008-03-19 | — | — | EP | disclosed |
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | disclosed |
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | disclosed |
| WO-2007046548-A1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-04-26 | — | — | WO | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| WO-2006127595-A1 | 5-AMINOPYRAZOLE CARBOXYLIC ACID DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203044-A1 | PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME | NLRP3, PYCARD, NLRP1 | POLB 4527/4885KMT2A 3325/4885THRB 2320/4885 |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | POLB 3038/4885KMT2A 4487/4885THRB 1767/4885 |
| US-20230382924-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | POLB 3442/4885KMT2A 4635/4885THRB 1180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.